Ventripoint Adds Hospital Networking Expert to Implementation Team
Toronto, Ontario, February 7, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that Dr. Andriy Shmatukha has joined the Ventripoint team as software developer to advance the Ventripoint products and technology.
“Medical imaging is dependent on technologies to deal with the storage, retrieval and manipulation of large image files needed for high-resolution cardiac scans and Dr. Shmatukha is an expert on these archiving protocols,” stated Desmond Hirson, President of Ventripoint. “We are fortunate to have his many years of experience in industry and the clinical settings on our team.”
Dr. Shmatukha is a qualified network administrator with over 18 years of medical device R&D experience with emphasis on diagnostics cardiac imaging, including the development of image analysis algorithms and associated software. At his tenure at GE Healthcare he was responsible for quality assurance of clinical trials for medical software. He is an inventor on multiple patents in image analysis algorithms and device hardware. As a research engineer at Sunnybrook Health Sciences Center (Toronto, Canada), he developed DICOM application software to manipulate medical images to allow them to be analysed and stored in a hospital Picture Archiving and Communication Systems (PACS) environment. At Utrecht University Medical Center (Utrecht, The Netherlands), he developed MRI imaging procedures and image analysis algorithms for real-time MRI guidance of minimally-invasive thermal therapies.
In other news, Ventripoint announces that it has entered into a consulting agreement for international financial and strategic advisory services with respect to international opportunities for a term of one year. Under the contract the Company has the option to pay the quarterly work fees of $30,000 in cash or in common shares, with the number of common shares being determined with reference to the market price at the time of issuance, and subject to the approval of the TSX Venture Exchange.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Corporation has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.